赛恩斯（688480）：2025H1业绩预告点评：费用、减值拖累业绩，开展药剂投资，股权激励锁定增长

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a decline in net profit for the first half of 2025, primarily due to increased expenses and impairment losses, despite revenue growth driven by operational services and product sales [7] - The company has initiated a stock incentive plan aimed at achieving significant growth in net profit from 2025 to 2027, reflecting confidence in future performance [7] - The company plans to expand its product offerings in the chemical sector, particularly in flotation agents and sodium sulfide, to capitalize on market demand [7] Financial Summary - The company expects total revenue to grow from 808.41 million RMB in 2023 to 1,724.02 million RMB by 2027, with a compound annual growth rate (CAGR) of approximately 16.86% [1] - The forecasted net profit for 2025 is adjusted to 163.15 million RMB, a decrease of 9.74% compared to the previous year, with a projected P/E ratio of 25.36 [1][7] - The company anticipates a significant increase in revenue and net profit over the next few years, with a target of 30% revenue growth in 2025 [7]